Host Sensing of Microbiota-Associated Metabolites in Gastrointestinal Graft-Versus-Host Disease: Cell-Specific Mechanisms and Pharmacological Opportunities
Future Pharmacology · 21.10.2026 · 6 (4) · 59
DOI: 10.3390/futurepharmacol6040059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 21.10.2026. Verfasst von Dianwen Yu und 6 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Gastrointestinal graft-versus-host disease (GI-GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Conditioning directly injures the intestinal epithelium, whereas antibiotics, nutritional disruption, and immunosuppression remodel the intestinal ecosystem; together, these exposures are associated with loss of obligate anaerobes and altered availability of microbiota- associated metabolites. This review examines how host tissues sense these metabolic changes and translate them into divergent biological outcomes.
Methods
We integrate evidence on directly produced microbial metabolites, including short-chain fatty acids, tryptophan-derived indoles, and desaminotyrosine, as well as microbially modified bile acids, host–microbial co-metabolites such as trimethylamine N-oxide, and emerging microbiota-associated compounds. We then examine receptor-mediated pathways involving FFAR2/3, HCAR2, AhR, PXR, FXR, TGR5, and VDR, as well as receptor-independent mechanisms such as HDAC inhibition and mTORC1-STING-dependent regeneration.
Results
We propose that metabolite activity in GI-GVHD is determined not by abundance alone, but by chemical form, concentration, tissue distribution, sensor identity, responding cell type, and disease stage. This framework explains how a metabolite may reinforce epithelial tolerance while promoting inflammatory myeloid or donor T-cell programs in another compartment. We further evaluate postbiotic replacement, receptor modulation, precision nutrition, defined microbial consortia, and fecal microbiota transplantation, highlighting pharmacokinetic, pharmacodynamic, infectious, and graft-versus-leukemia considerations.
Conclusions
Cell- and compartment-resolved metabolite pharmacology may enable tissue-protective strategies that limit GI-GVHD without broadly suppressing antitumor immunity.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, D., Zhang, R., Shang, T., Wen, T., Luo, Y., Liu, Y., & Shi, S. (2026). Host Sensing of Microbiota-Associated Metabolites in Gastrointestinal Graft-Versus-Host Disease: Cell-Specific Mechanisms and Pharmacological Opportunities. Future Pharmacology, 6(4), 59. https://doi.org/10.3390/futurepharmacol6040059
Vancouver
Yu D, Zhang R, Shang T, Wen T, Luo Y, Liu Y, et al. Host Sensing of Microbiota-Associated Metabolites in Gastrointestinal Graft-Versus-Host Disease: Cell-Specific Mechanisms and Pharmacological Opportunities. Future Pharmacology. 2026;6(4):59. doi:10.3390/futurepharmacol6040059
BibTeX
@article{Yu2026,
author = {Yu, Dianwen and Zhang, Rui and Shang, Tianze and Wen, Tian and Luo, Yong and Liu, Yani and Shi, Shaojun},
title = {Host Sensing of Microbiota-Associated Metabolites in Gastrointestinal Graft-Versus-Host Disease: Cell-Specific Mechanisms and Pharmacological Opportunities},
journal = {Future Pharmacology},
year = {2026},
volume = {6},
number = {4},
pages = {59},
doi = {10.3390/futurepharmacol6040059}
}
EUVIMED